EGFR Mutation Targeting Molecular Probe for PET Imaging

Inclusion criteria

• Male and female, aged 18-75 years old (including 18 and 75 years old), ECOG score 0 or 1.
• Patients could understand and sign the informed consent form voluntarily with good compliance.
• Patients with histologically or cytologically or clinically confirmed lung cancer with measurable disease.
• Women had to be using an effective contraceptive method (effective contraceptive means sterilisation, intrauterine hormonal devices, condoms, contraceptives/pills, sexual abstinence, or partner's removal of the vas deferens) during the study and for 6 months after the study. Men should consent to subjects who must use contraception during the study period and for 6 months after the end of the study period.
• Predicted survival greater than 3 months;

Exclusion criteria

• Severe hepatic or renal dysfunction;
• Pregnant or nursing;
• Known allergy to the investigational drug or its excipients in study;
• Unable to comply with the PET/CT imaging procedures;
• Claustrophobia or other psychiatric disorders;
• Other conditions deemed unsuitable for participation in the trial;